Artículos de revistas
Growth In Patients With The Salt-wasting Form Of Congenital Adrenal Hyperplasia During The First Two Years Of Life [crescimento De Pacientes Com Hyperplasia Congênita Das Supra-renais, Forma Perdedora De Sal, Nos Dois Primeiros Anos De Vida]
Registro en:
Revista Brasileira De Saude Materno Infantil. , v. 9, n. 4, p. 415 - 421, 2009.
15193829
2-s2.0-74949083481
Autor
Mendes-dos-Santos C.T.
de Lemos-Marini S.H.V.
Baptista M.T.M.
Guerra-Junior G.
De-Mello M.P.
Morcillo A.M.
Institución
Resumen
Objectives: to assess the growth and nutritional recovery of patients with the classical salt-wasting form of congenital adrenal hyperplasia in the first two years of life. Methods: z scores for weight and height were calculated for 21 patients at birth, on the occasion of the first medical consultation and at one and two years of age. The concentrations of 17-hydroxyprog-esterone, androstenedione and the doses of hydrocortisone prescribed at the first medical concentrations up to the age of two years were determined (at one and two years of age respectively). Results: the mean age for the first medical consultation was 36.7 days. The z score for weight at birth was -0.23±1.4; on the occasion of the first consultation -2.31±1.3; at the age of one year -1.43±1.6 and at the age of two years -0.77± 1.3. The z score for height at birth was -0.69±2.3; on the occasion of the first consultation -1.87±1.7; at one year of age - 1.68±1.1 and at two years -1.07±1.0. The difference between the scores at two years of age and on the occasion of the first medical consultation was 1.54±1.7 for weight and 0.80±1.6 for height. The mean dosage of hydrocortisone prescribed was 21.3 and 19.9 mg/m2/day for periods 1 and 2 and the concentrations (ng/dL) of 17-hydroxyprogesterone and androstenedione were 9.1 and 0.14 for period 1 and 4.4 and 0.27 for period 2. Conclusions: nutritional recovery was observed to occur on treatment and, at two years of age, weight and height are normal, although below the average for the population at large. 9 4 415 421 Technical report: Congenital adrenal hyperplasia (2000) Pediatrics, 106, pp. 1511-1518. , American Academy of Pediatrics Nguyen, A.T., Brown, J.J., Warne, G.L., Growth in congenital adrenal hyperplasia (2006) Indian J Pediatr, 73, pp. 89-93 New, M.I., An update of congenital adrenal hyperplasia (2004) Ann N Y Acad Sci, 1038, pp. 14-43 Pang, S., Congenital adrenal hyperplasia (1997) Endocrinol Metab Clin North Am, 26, pp. 853-891 Forest, M.G., Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (2004) Hum Reprod Update, 10, pp. 469-485 Miller, W.L., Genetics, diagnosis, and management of 21-hydroxilase deficiency (1994) J Clin Endocrinol Metab, 78, pp. 241-246 Girgis, R., Winter, J.S.D., The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyper-plasia (1997) J Clin Endocrinol Metab, 82 (3), pp. 926-929 Eugster, E.A., Dimeglio, L.A., Wright, J.C., Freidenberg, G.R., Seshadri, R., Pescovitz, O.H., Height outcome in congenital adrenal hyperplasia caused by 21 hydroxylase deficiency: A meta-analysis (2001) J Pediatr, 138, pp. 26-32 Cameron, F.J., Kaymakci, B., Byrt, E.A., Ebeling, P.R., Warne, G.L., WalkJD. Bone mineral density and body composition in congenital adrenal hyperplasia (1995) J Clin Endocrinol Metab, 80, pp. 2238-2243 Cornean, R.E., Hindmarsh, P.C., Brook, C.G., Obesity in 21-hydroxylase deficient patients (1998) Arch Dis Child, 78, pp. 261-263 Migeon, C.J., Donohoue, P.A., Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. Its molecular basis and its remaining therapeutic problems (1991) Endocrinol Metab Clin North Am, 20, pp. 277-296 Merke, D.P., Bornstein, S.R., Congenital adrenal hyperplasia (2005) Lancet, 365, pp. 2125-2136 Schwartz, R.P., Back to basics: Early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia (2001) J Pediatr, 138, pp. 3-5 Manoli, I., Kanaka-Gantenbein, C.H., Voutetakis, A., Maniati-Christidi, M., Dacou-Voutetakis, A., Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: Factors influencing the outcome (2002) Clin Endocrinol (oxf), 57, pp. 669-676 Savage, M.O., Scommegna, S., Carroll, P.V., Ho, J.T., Monson, J.P., Besser, G.M., Grossman, A.B., Growth in disorders of adrenal hyperfunction (2002) Horm Res, 58 (SUPPL. 1), pp. 39-43 van der Kamp, H.J., Otten, B.J., Buitenweg, N., de Munick Keiser-Schrama, S.M.P.F., Oostdijk, W., Jansen, M., Delemarre-de-Waal, H.A., Wit, J.M., Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients (2002) Arch Dis Child, 87, pp. 139-144 Lemos-Marini, S.H.V., Guerra-Júnior, G., Morcillo, A.M., Baptista, M.T.M., Silva, L.O., Maciel-Guerra, A.T., Hiperplasia congênita das supra-renais por deficiência da 21-hidroxilase: Altura final de 27 pacientes com a forma clássica (2005) Arq Bras Endocrinol Metab, 49, pp. 902-907 Hargitai, G., Sólyom, J., Battelino, T., Lebl, J., Pribilincová, Z., Hauspie, R., Kovács, J., Frisch, H., Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study (2001) Horm Res, 55, pp. 161-171. , and the MEWPE-CAH study group (2000) Cdc Growth Charts: United States, , http://www.cdc.gov/growthcharts/, National Center for Health Statistics, [cited on 2007 mar 8] Available from Ramos, C.C.A., Bento, L.R., Gonçalves, E.M., De-Mello, M.P., Baptista, M.T.M., Lemos-Marini, S.H.V., Guerra-Junior, G., Avaliação do crescimento, do controle laboratorial e da corticoterapia em um grupo de pacientes com a forma clássica da deficiência da 21-hidroxilase (2007) Rev Paul Pediatr, 25, pp. 317-323 Gussinye, M., Potau, N., Vicens-Calvet, E., Albisu, M.A., Yeste, D., Ibanez, L., Audí, L., Carrascosa, A., Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form (1997) Med Clin (barc), 108, pp. 87-90